Identification of beta2-microglobulin as a potential target for ovarian cancer

Cancer Biology and Therapy

Volumn 8, Issue 24, 2009, Pages 2323-2328

  Han, Shuo Yang ^a   Yu, Li ^a,b   Hong, Xin Deng ^a   Feng, Peng ^a  

^a SICHUAN UNIVERSITY   (China)

^b First People's Hospital of Lianyungang City   (China)

Author keywords

Antibody therapy; Apoptosis; Beta2 microglobulin; Ovarian cancer; PI3K AKT; SEREX; SKOV3

Indexed keywords

BETA 2 MICROGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANCHORAGE INDEPENDENT GROWTH; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; OVARY CANCER; PROTEIN EXPRESSION;

EID: 75749147983     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.24.9982     Document Type: Article

References (35)

1. Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC. The biology of ovarian cancer. Semin Oncol 1998; 25:281-304.
2. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, et al. Focus on epithelial ovarian cancer. Cancer Cell 2004; 5:19-24.
3. Markman M. Pharmaceutical management of ovarian cancer: current status. Drugs 2008; 68:771-89.
4. Modesitt SC, Jazaeri AA. Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Expert Opin Pharmacother 2007; 8:2293-305.
5. Richardson A, Kaye SB. Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance. Drug Resist Updat 2005; 8:311-21.
6. Vasey PA. Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br J Cancer 2003; 89:23-8.
7. von Mehren M, Adams GP, Weiner LM. Monoclonal antibody therapy for cancer. Annu Rev Med 2003; 54:343-69.
8. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23:1147-57.
9. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008; 26:4672-8.
10. Messersmith WA, Ahnen DJ. Targeting EGFR in colorectal cancer. N Engl J Med 2008; 359:1834-6.
11. Poncet B, Bachelot T, Colin C, Ganne C, Jaisson-Hot I, Orfeuvre H, et al. Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis. Am J Clin Oncol 2008; 31:363-8.
12. Maloney DG. Mechanism of action of rituximab. Anticancer Drugs 2001; 12:1-4.
13. Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, et al. Human neoplasms elicit multiple specific immune response in the autologous host. Proc Natl Acad Sci USA 1995; 92:11810-3.
14. Hyafil F, Strominger JL. Dissociation and exchange of the beta2-microglobulin subunit of HLA-A and HLA-B antigens. Proc Nat Acad Sci USA 1979; 76:5834-8.
15. Parker KC, Strominger JL. Subunit interactions of class I histocompatibility antigens. Biochemistry 1985; 24:5543-50.
16. Klein T, Levin I, Niska A, Koren R, Gal R, Schachter J, et al. Correlation between tumour and serum beta2m expression in patients with breast cancer. Eur J Immunogenet 1996; 23:417-23.
17. Cooper EH, Plesner T. Beta-2-microglobulin review: its relevance in clinical oncology. Med Pediatr Oncol 1980; 8:323-34.
18. Molica S, Levato D, Cascavilla N, Levato L, Musto P. Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia. Eur J Haematol 1999; 62:117-22.
19. Shvidel L, Hofstein R, Berrebi A. Serum beta-2 microglobulin as a marker of B-cell activation in chronic lymphoid malignancies. Am J Hematol 1996; 53:148-9.
20. Bataille R, Durie BG, Grenier J. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol 1983; 55:439-47.
21. Alexanian R, Barlogie B, Fritsche H. Beta2 microglobulin in multiple myeloma. Am J Hematol 1985; 20:345-51.
22. Abdul M, Hoosein N. Changes in beta-2 microglobulin expression in prostate cancer. Urol Oncol 2000; 5:168-72.
23. Rasmuson T, Grankvist K, Ljungberg B. Serum beta2-microglobulin and prognosis of patients with renal cell carcinoma. Acta Oncol 1996; 35:479-82.
24. Shrout J, Yousefzadeh M, Dodd A, Kirven K, Blum C, Graham A, et al. Beta(2)microglobulin mRNA expression levels are prognostic for lymph node metastasis in colorectal cancer patients. Br J Cancer 2008; 98:1999-2005.
25. Xie J, Wang Y, Freeman ME, Barlogie B, Yi Q. Beta2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood 2003; 101:4005-12.
26. Scheffer GL, de Jong MC, Monks A, Flens MJ, Hose CD, Izquierdo MA, et al. Increased expression of beta2-microglobulin in multidrug-resistant tumour cells. Br J Cancer 2002; 86:1943-50.
27. Nomura T, Huang WC, Zhau HE, Wu D, Xie Z, Mimata H, et al. Beta2-microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis. Clin Cancer Res 2006; 12:7294-305.
28. Huang WC, Wu D, Xie Z, Zhau HE, Nomura T, Zayzafoon M, et al. Beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res 2006; 66:9108-16.
29. Centrella M, McCarthy TL, Canalis E. Beta2-microglobulin enhances insulin-like growth factor I receptor levels and synthesis in bone cell cultures. J Biol Chem 1989; 264:18268-71.
30. Due C, Simonsen M, Olsson L. The major histocompatibility complex class I heavy chain as a structural subunit of the human cell membrane insulin receptor: implications for the range of biological functions of histocompatibility antigens. Proc Natl Acad Sci USA 1986; 83:6007-11.
31. Hernádi Z, Molnár V, Juhász B, Pólka R, Margitai B. Predictive value of the tumor marker combination CA-125 and beta-2-microglobulin in ovarian cancer. Zentralbl Gynakol 1992; 114:6-9.
32. Nomura T, Huang WC, Seo S, Zhau HE, Mimata H, Chung LW. Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma. J Urol 2007; 178:292-300.
33. Huang WC, Havel JJ, Zhau HE, Qian WP, Lue HW, Chu CY, et al. Beta2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells. Clin Cancer Res 2008; 14:5341-7.
34. Yang J, Zhang X, Wang J, Qian J, Zhang L, Wang M, et al. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood 2007; 110:3028-35.
35. Yang J, Qian J, Wezeman M, Wang S, Lin P, Wang M, et al. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell 2006; 10:295-307.